This study investigated why reports of side effects (adverse drug reactions or ADRs) from a common HIV medication in Uganda are often incomplete, which hinders effective drug safety monitoring.
Study Purpose and Method
The research aimed to understand the barriers to complete reporting of ADRs for dolutegravir (DTG), the preferred first-line HIV treatment in Uganda. Despite good reporting systems, incomplete data makes it hard for regulators to spot safety issues.
Using a qualitative design, researchers conducted 36 in-depth interviews with HIV clinicians and 8 focus groups with 56 people living with HIV (PWH) across 12 health facilities in Uganda between August and October 2024.
Key Findings: Three Levels of Barriers
The analysis identified obstacles at three levels that lead to incomplete reports:
- Patient-Based Barriers
- Long Appointments: Six-month gaps between clinic visits make it hard for patients to recall details of side effects.
- Withholding Information: Patients sometimes do not disclose their use of herbal medicines alongside treatment.
- Fear of Treatment Change: Patients perceive DTG as superior and may under-report problems to avoid being switched to a different drug.
- Health Workforce Barriers
- “Professional Agency”: A key finding was that clinicians often manage side effects individually at the patient level rather than formally reporting them to the national system.
- Fear of Scrutiny: Health workers may avoid providing complete details (like exact dosage) in reports due to fear of blame or investigation afterward.
- Low Awareness Among Mid-Cadres: Nurses and other mid-level staff often are not fully aware of how crucial complete reports are for regulatory action.
- Health System Barriers
- Shortage of Resources: Facilities lack the supplies and lab capacity to properly investigate suspected ADRs.
- Lack of Incentives: There are no rewards or motivations for health workers to take the extra time to file thorough reports.
Conclusion and Significance
The study concludes that incomplete ADR reporting is a multi-faceted problem rooted in patient, workforce, and system challenges.
The findings are critical for improving pharmacovigilance (drug safety monitoring) not only in Uganda but in other countries with similar healthcare settings. Ensuring complete data is essential for regulators to make timely decisions that protect patient safety, especially as new side effects of long-term DTG use may emerge.
